Related Experiment Videos
Childhood myelodysplasia
1Department of Pediatric Hematology and Oncology, B.J. Wadia Hospital for Children, Parel, Bombay.
Insights
Childhood myelodysplasia is a significant hematological malignancy in children, often presenting aggressively. This study highlights its prevalence and potential to transform into acute leukemia, emphasizing the need for early diagnosis and intervention.
Area of Science:
- Pediatric Hematology
- Oncology
- Clinical Hematology
Background:
- Childhood myelodysplasia (CMD) is a rare but serious group of bone marrow disorders.
- Diagnosis relies on specific criteria, such as the French-American-British (FAB) Cooperative Group classification.
- CMD represents a notable percentage of pediatric hematological malignancies.
Purpose of the Study:
- To present the clinical and hematological characteristics of childhood myelodysplasia.
- To analyze the incidence, subtypes, and outcomes of CMD in a pediatric cohort.
- To investigate the transformation rate of CMD into acute leukemias.
Main Methods:
- Retrospective analysis of clinical data from 29 children under 12 years old diagnosed with primary myelodysplasia.
- Classification of cases according to FAB criteria.
- Evaluation of symptom duration, disease subtypes, evolution to acute leukemia, and survival rates.
Main Results:
- The study included 29 children (24 males, 5 females) with a median age of 2.5 years.
- Common subtypes included refractory anemia (15 cases) and chronic myelomonocytic leukemia (10 cases).
- Five patients progressed to acute myeloid leukemia and four to acute lymphatic leukemia, with a median preleukemic phase of 7 months. Overall survival was poor (5-9 months).
Conclusions:
- Childhood myelodysplasia is not uncommon and has an aggressive clinical course.
- CMD frequently evolves into acute leukemia, underscoring the importance of timely diagnosis and management.
- Further research into effective therapeutic strategies for pediatric myelodysplasia is warranted.
Abstract:
The clinical data and hematological features of 29 children, under the age of 12 years, with primary myelodysplasia are presented. The diagnosis was made using the FAB (French-American-British) Cooperative Group criteria. There were 24 males and 5 females aged 4 months to 12 years (median 2.5 years) with marked male preponderance. Childhood myelodysplasia constituted 16% of all hematological malignancies and 36.7% of acute myeloid leukemias. The median duration of symptoms prior to diagnosis was 3 months. There were 15 cases of refractory anemia, one of refractory anemia with excess blasts, 3 of refractory anemia with excess blasts in transformation and 10 cases of chronic myelomonocytic leukemia. Five patients evolved to acute myeloid and 4 to acute lymphatic leukemia. The median duration of preleukemic phase in these patients was 7 months (range 4-29 months). The overall mean survival was short (5-9 months) in all the subgroups. Besides supportive therapy in most patients, two patients were treated with etoposide, one with alfa interferon 2b and one with high dose methylprednisolone. Our results show that myelodysplasia is not infrequent in children. The disease has an aggressive clinical course and may evolve into acute leukemia.